SCHEMBL5256289

SCHEMBL5256289

COc1cc2cc(C(=O)O)c(C(=O)OC(=O)c3cc4cc(OC)c(OC)cc4cc3C(=O)O)cc2cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.56
ALDH1A1 P00352 4/20 0.56
HPGD P15428 3/20 0.56
LCK P06239 1/20 0.50
FYN P06241 1/20 0.50
HSD17B10 Q99714 2/20 0.46
CA12 O43570 3/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA4 P22748 3/20 0.43
CA6 P23280 3/20 0.43
CA7 P43166 3/20 0.43
CA9 Q16790 3/20 0.43
CA14 Q9ULX7 3/20 0.43
TPMT P51580 1/20 0.43
MYC P01106 1/20 0.42
CA3 P07451 2/20 0.42
CA5A P35218 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5251625 0.89 KDM4E (0.56) KDM4EALDH1A1HPGDLCKFYN
SCHEMBL2433986 0.86 ALDH1A1 (0.39) KDM4EALDH1A1HPGDHSD17B10CA12
SCHEMBL2433666 0.84 GPR35 (0.38) KDM4EALDH1A1HPGDHSD17B10CA12
SCHEMBL22149604 0.82 KDM4E (0.78) KDM4EALDH1A1HPGDLCKFYN
SCHEMBL11271721 0.81 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10CA12
SCHEMBL26882982 0.80 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL1417516 0.80 LCK (0.72) KDM4EALDH1A1HPGDLCKFYN
SCHEMBL30415497 0.80 LCK (0.72) KDM4EALDH1A1HPGDLCKFYN
SCHEMBL28719929 0.79 KDM4E (0.63) KDM4EALDH1A1HPGDLCKFYN
SCHEMBL887647 0.77 ALDH1A1 (0.39) KDM4EALDH1A1HPGDLCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242382-B1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH CORP (US) 2007-02-07 EP disclosed
US-20060247217-A1 Tricyclic protein kinase inhibitors BERGER DAN M 2006-11-02 US disclosed
US-7105531-B2 Tricyclic protein kinase inhibitors WYETH (US) 2006-09-12 US disclosed
US-20040110762-A1 Tricyclic protein kinase inhibitors WYETH 2004-06-10 US disclosed
US-6638929-B2 Compounds containing nicotinonitrile rings; anticarcinogenic and -tumor agents; polycystic kidney disease and colonic polyps; antiproliferative agents; angiogenesis inhibitors; restenosis; atherosclerosis; angiofibromas; hemangiomas; WYETH 2003-10-28 US disclosed
EP-1242382-A1 TRICYCLIC PROTEIN KINASE INHIBITORS Wyeth (US) 2002-09-25 EP disclosed
US-20010051620-A1 Tricyclic protein kinase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 2001-12-13 US disclosed
WO-2001047892-A1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH (US) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110762-A1 Tricyclic protein kinase inhibitors CDK1, CDKN1A, CDK2 KDM4E 1644/4885ALDH1A1 3285/4885HPGD 3295/4885
US-20060247217-A1 Tricyclic protein kinase inhibitors CDK1, CDKN1A, CDK2 KDM4E 1432/4885ALDH1A1 3511/4885HPGD 3246/4885
US-20010051620-A1 Tricyclic protein kinase inhibitors CDK1, CHEK1, ABL1 KDM4E 1527/4885ALDH1A1 4120/4885HPGD 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.